Programmed cell death‑1/programmed cell death‑ligand 1 inhibitors exert antiapoptosis and antiinflammatory activity in lipopolysaccharide stimulated murine alveolar macrophages

Jia,Lingling; Liu,Kai; Fei,Teng; Liu,Qian; Zhao,Xiwei; Hou,Linyi; Zhang,Wenkai

doi:10.3892/etm.2021.9831

Programmed cell death‑1/programmed cell death‑ligand 1 inhibitors exert antiapoptosis and antiinflammatory activity in lipopolysaccharide stimulated murine alveolar macrophages

Authors:
- Lingling Jia
- Kai Liu
- Teng Fei
- Qian Liu
- Xiwei Zhao
- Linyi Hou
- Wenkai Zhang
View Affiliations

Affiliations: Department of Thoracic Surgery, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China, Department of Intensive Care Unit, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China
Published online on: February 24, 2021 https://doi.org/10.3892/etm.2021.9831
Article Number: 400
Copyright: © Jia et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute lung injury caused by sepsis remains one of the most difficult challenges faced by patients in intensive care units and is associated with a high mortality rate. The aim of the present study was to investigate whether programmed cell death (PD)‑1/programmed cell death‑ligand 1 (PD‑L1) inhibitors reduce alveolar macrophage apoptosis, reduce inflammatory factor release and relieve inflammation. For this purpose, murine alveolar macrophages, MH‑S, were cultured and divided into control, lipopolysaccharide (LPS) and LPS+BMS‑1 (PD‑1/PD‑L1 inhibitors) groups. LPS (10 ng/ml) was added to the LPS and LPS+BMS‑1 groups for 24 h and PD‑1/PD‑L1 inhibitor BMS‑1 (1 µmol/l) was added to the LPS+BMS‑1 group for 72 h. PD‑1 mRNA expression was detected using reverse transcription‑quantitative PCR and PD‑1 protein expression was detected using western blotting in the control, LPS and LPS+BMS‑1 groups of macrophages. MH‑S apoptosis was detected using flow cytometry with Annexin V/PI staining. The levels of the inflammatory factors interleukin (IL)‑1β, IL‑6, tumor necrosis factor (TNF)‑α and IL‑10 were detected by ELISA. Murine alveolar macrophages expressed PD‑1 at both the molecular and protein levels and PD‑1 expression was increased in MH‑S cells stimulated with LPS. Compared with the LPS group, the expression of PD‑1 in the LPS+BMS‑1 group was significantly decreased. Flow cytometry demonstrated that there was increased apoptosis of alveolar macrophages in the LPS group compared with the control group, whereas, alveolar macrophages notably decreased apoptosis in the LPS+BMS‑1 group compared with the LPS group. There was no statistical difference between the control group and the LPS+BMS‑1 group. IL‑1β, IL‑6, TNF‑α and IL‑10 were increased in the LPS group compared with the control group. The levels of IL‑1β, IL‑6 and TNF‑α in the LPS+BMS‑1 group were lower compared with those in the LPS group whereas IL‑10 was further increased. In vitro, the PD‑1/PD‑L1 inhibitor, BMS‑1, decreases alveolar macrophage apoptosis compared with the LPS group to maintain effective immune clearance and reduce inflammatory factor release. This decreased the inflammatory response and reduced acute lung injury caused by sepsis. Therefore, PD‑1/PD‑L1 inhibitors may be a potential therapeutic target for acute lung injury in patients with sepsis.

View Figures

View References

1	Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, et al: The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 315:801–810. 2016.PubMed/NCBI View Article : Google Scholar
2	Kempker JA and Martin GS: The changing epidemiology and definitions of sepsis. Clin Chest Med. 37:165–179. 2016.PubMed/NCBI View Article : Google Scholar
3	Wang YM, Ji R, Chen WW, Huang SW, Zheng YJ, Yang ZT, Qu HP, Chen H, Mao EQ, Chen Y and Chen EZ: Paclitaxel alleviated sepsis-induced acute lung injury by activating MUC1 and suppressing TLR-4/NF-κB pathway. Drug Des Devel Ther. 13:3391–3404. 2019.PubMed/NCBI View Article : Google Scholar
4	Johnson ER and Matthay MA: Acute lung injury: Epidemiology, pathogenesis, and treatment. J Aerosol Med Pulm Drug Deliv. 23:243–252. 2010.PubMed/NCBI View Article : Google Scholar
5	Zahar JR, Timsit JF, Garrouste-Orgeas M, Français A, Vesin A, Descorps-Declere A, Dubois Y, Souweine B, Haouache H, Goldgran-Toledano D, et al: Outcomes in severe sepsis and patients with septic shock: Pathogen species and infection sites are not associated with mortality. Crit Care Med. 39:1886–1895. 2011.PubMed/NCBI View Article : Google Scholar
6	Matthay MA, Ware LB and Zimmerman GA: The acute respiratory distress syndrome. J Clin Invest. 122:2731–2740. 2012.PubMed/NCBI View Article : Google Scholar
7	Huang C, Zheng H, He W, Lu G, Li X, Deng Y and Zeng M: Ghrelin ameliorates the human alveolar epithelial A549 cell apoptosis induced by lipopolysaccharide. Biochem Biophys Res Commun. 474:83–90. 2016.PubMed/NCBI View Article : Google Scholar
8	Gill SE, Rohan M and Mehta S: Role of pulmonary microvascular endothelial cell apoptosis in murine sepsis-induced lung injury in vivo. Respir Res. 16(109)2015.PubMed/NCBI View Article : Google Scholar
9	Li B, Fang J, Zuo Z, Yin S, He T, Yang M, Deng J, Shen L, Ma X, Yu S, et al: Activation of porcine alveolar macrophages by actinobacillus pleuropneumoniae lipopolysaccharide via the toll-like receptor 4/NF-κB-mediated pathway. Infect Immun. 86:e00642–17. 2018.PubMed/NCBI View Article : Google Scholar
10	Moldoveanu B, Otmishi P, Jani P, Walker J, Sarmiento X, Guardiola J, Saad M and Yu J: Inflammatory mechanisms in the lung. J Inflamm Res. 2:1–11. 2009.PubMed/NCBI
11	Pahuja M, Tran C, Wang H and Yin K: Alveolar macrophage suppression in sepsis is associated with high mobility group box 1 transmigration. Shock. 29:754–760. 2008.PubMed/NCBI View Article : Google Scholar
12	Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, et al: Expression of programmed death 1 ligands by murine T cells and APC. J Immunol. 169:5538–5545. 2002.PubMed/NCBI View Article : Google Scholar
13	Keir ME, Butte MJ, Freeman GJ and Sharpe AH: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 26:677–704. 2008.PubMed/NCBI View Article : Google Scholar
14	Shinohara T, Taniwaki M, Ishida Y, Kawaichi M and Honjo T: Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics. 23:704–706. 1994.PubMed/NCBI View Article : Google Scholar
15	Hassan SS, Akram M, King EC, Dockrell HM and Cliff JM: PD-1, PD-L1 and PD-L2 gene expression on T-cells and natural killer cells declines in conjunction with a reduction in PD-1 protein during the intensive phase of tuberculosis treatment. PLoS One. 10(e0137646)2015.PubMed/NCBI View Article : Google Scholar
16	Dong H, Zhu G, Tamada K and Chen L: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999.PubMed/NCBI View Article : Google Scholar
17	Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2:261–268. 2001.PubMed/NCBI View Article : Google Scholar
18	Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL and Anders RA: Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 20:5064–5074. 2014.PubMed/NCBI View Article : Google Scholar
19	Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y, Swan R, Kherouf H, Monneret G, Chung CS and Ayala A: PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci USA. 106:6303–6308. 2009.PubMed/NCBI View Article : Google Scholar
20	Bao X, Sun H and Yang Q: The role and mechanism of costimulatory molecular programmed death ligand-1 in acute lung injury. Zhonghua Crisis Emerg Med. 28:498–503. 2016.
21	Zhao Y, Jia Y, Shi T, Wang W, Shao D, Zheng X, Sun M, He K and Chen L: Depression promotes hepatocellular carcinoma progression through a glucocorticoids mediated up-regulation of PD-1 expression in tumor infiltrating NK cells. Carcinogenesis: Feb 4, 2019 (Epub ahead of print). doi: 10.1093/carcin/bgz017.
22	Zhou Z, Su Y and Fa XE: Isorhynchophylline exerts anti-inflammatory and anti-oxidative activities in LPS-stimulated murine alveolar macrophages. Life Sci. 223:137–145. 2019.PubMed/NCBI View Article : Google Scholar
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
24	Niesler U, Palmer A, Radermacher P and Huber-Lang MS: Role of alveolar macrophages in the inflammatory response after trauma. Shock. 42:3–10. 2014.PubMed/NCBI View Article : Google Scholar
25	Kubota Y, Iwasaki Y, Harada H, Yokomura I, Ueda M, Hashimoto S and Nakagawa M: Role of alveolar macrophages in Candida-induced acute lung injury. Clin Diagn Lab Immunol. 8:1258–1262. 2001.PubMed/NCBI View Article : Google Scholar
26	Yang L, Zhang Z, Zhuo Y, Cui L, Li C, Li D, Zhang S, Cui N, Wang X and Gao H: Resveratrol alleviates sepsis-induced acute lung injury by suppressing inflammation and apoptosis of alveolar macrophage cells. Am J Transl Res. 10:1961–1975. 2018.PubMed/NCBI
27	Fu Y, Zhou J, Liu K, Hou L and Zhang W: Effects of miR-155 on IL-6, IL-10 and MIP-2 in alveolar macrophages of acute lung injury induced by sepsis. Chin J Crit Care Med. 5:159–164. 2019.
28	Nam S, Lee A, Lim J and Lim JS: Analysis of the expression and regulation of PD-1 protein on the surface of myeloid-derived suppressor cells (MDSCs). Biomol Ther (Seoul). 27:63–70. 2019.PubMed/NCBI View Article : Google Scholar
29	Mitsi E, Kamng'ona R, Rylance J, Solórzano C, Jesus Reiné J, Mwandumba HC, Ferreira DM and Jambo KC: Human alveolar macrophages predominately express combined classical M1 and M2 surface markers in steady state. Respir Res. 19(66)2018.PubMed/NCBI View Article : Google Scholar
30	Italiani P and Boraschi D: From monocytes to M1/M2 macrophages: Phenotypical vs functional differentiation. Front Immunol. 5(514)2014.PubMed/NCBI View Article : Google Scholar
31	Yin D, Wang W, Han W and Fan C: Targeting Notch-activated M1 macrophages attenuate lung tissue damage in a rat model of ventilator induced lunginjury. Int J Mol Med. 44:1388–1398. 2019.PubMed/NCBI View Article : Google Scholar